Materials engineering strategies for cancer vaccine adjuvant development-Reference-Cited by-同舟云学术

Materials engineering strategies for cancer vaccine adjuvant development

Published:2023 Issue:9 Volume:52 Page:2886-2910
ISSN:0306-0012
Container-title:Chemical Society Reviews
language:en
Short-container-title:Chem. Soc. Rev.

Author:

Zhang Xuanbo¹²,Yang Bowei¹,Ni Qianqian¹³⁴,Chen Xiaoyuan¹³⁴⁵^ORCID

Affiliation:

1. Departments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore 119074, Singapore

2. Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China

3. Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore

4. Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore

5. Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore, 138673, Singapore

Abstract

In this Review, we have summarized advances in the development of cancer vaccine adjuvants, including chemically engineered molecular agonists, versatile self-adjuvanting materials, and genetically engineered bio-derived materials.

Funder

National University of Singapore

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/CS/D2CS00647B

Reference122 articles.

1. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways

2. Cancer treatment and survivorship statistics, 2022

3. Emerging concepts in the science of vaccine adjuvants